From a model on a screen to medicine in the world.

The next step can't happen on a computer. It happens in the lab.

First, we find the lead. Help us test several new generations of the rigidified HIV E-vaccine candidate and compare them head-to-head against the unoptimized originals. Across the groups we measure how often the immune system raises IgG antibodies to the conserved 421–433 site, how broadly those antibodies neutralize HIV, and how precisely they bind. The lead is the rare antibody with ideal 1:1 binding stoichiometry and the highest neutralizing titer.

The bigger prize

Then comes the audacious part. The same antibodies might not only prevent HIV. They might help clear it from people already living with the virus.

We administer the lead neutralizing IgGs to HIV-infected, ART-suppressed humanized mice and measure two things: the circulating virus (viral load) and the latent cellular reservoir, the dormant provirus that today's drugs can't reach. Reducing that reservoir is the path toward a functional cure.

HERE IS OUR TIMELINE

April 2026

UCSD + ARF produce the optimized E-vaccine structure

December 2026

Animal-model validation studies

2027

Present the animal data to major funders and pharma partners for human-trial support

2029

Clinical trials with a global testing partner.

HIV E-Vaccine Animal Studies